0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Protein > VEGF R2 > KDR-H82E5

Biotinylated Human VEGF R2 / KDR Protein, Avitag™,His Tag

Order Now

  • Synonym
    KDR,CD309,FLK1,VEGFR,VEGFR2
  • Source
    Biotinylated Human VEGF R2, Avitag,His Tag(KDR-H82E5) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823).
    Predicted N-terminus: Ala 20
  • Molecular Characterization
    VEGF R2 Structure

    This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.

    The protein has a calculated MW of 85.9 kDa. The protein migrates as 120-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
VEGF R2 SDS-PAGE

Biotinylated Human VEGF R2, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 VEGF R2 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (QC tested).

 VEGF R2 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).

Bioactivity-BLI
 VEGF R2 BLI

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity-FACS
 VEGF R2 FACS

2e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No.KDR-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

  • Background
    Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €350.00

Price(EUR) : €1540.00

Recommended Products
Placa recubierta de estreptavidina

Price(EUR) : €30.00

Price(EUR) : €140.00

Estreptavidina-HRP

Price(EUR) : €50.00

Price(EUR) : €120.00

Perlas magnéticas™ Estreptavidina

Price(EUR) : €140.00

Price(EUR) : €230.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:17 Details
  • Number of Drugs in Clinical Trials:52 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje